Pro-Dex (PDEX) Competitors $47.27 -0.26 (-0.55%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$48.51 +1.24 (+2.63%) As of 07/17/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDEX vs. EMBC, BBNX, AVNS, BVS, KIDS, RXST, AXGN, BFLY, SMLR, and DCTHShould you be buying Pro-Dex stock or one of its competitors? The main competitors of Pro-Dex include Embecta (EMBC), Beta Bionics (BBNX), AVANOS MEDICAL (AVNS), Bioventus (BVS), OrthoPediatrics (KIDS), RxSight (RXST), AxoGen (AXGN), Butterfly Network (BFLY), Semler Scientific (SMLR), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry. Pro-Dex vs. Its Competitors Embecta Beta Bionics AVANOS MEDICAL Bioventus OrthoPediatrics RxSight AxoGen Butterfly Network Semler Scientific Delcath Systems Pro-Dex (NASDAQ:PDEX) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Do analysts recommend PDEX or EMBC? Pro-Dex presently has a consensus price target of $56.00, suggesting a potential upside of 18.47%. Embecta has a consensus price target of $19.00, suggesting a potential upside of 92.89%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than Pro-Dex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pro-Dex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk & volatility, PDEX or EMBC? Pro-Dex has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Is PDEX or EMBC more profitable? Pro-Dex has a net margin of 14.61% compared to Embecta's net margin of 4.89%. Pro-Dex's return on equity of 29.08% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets Pro-Dex14.61% 29.08% 16.19% Embecta 4.89%-19.67%12.27% Which has preferable earnings and valuation, PDEX or EMBC? Embecta has higher revenue and earnings than Pro-Dex. Embecta is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPro-Dex$53.84M2.86$2.13M$2.8016.88Embecta$1.12B0.51$78.30M$0.9010.94 Do institutionals & insiders have more ownership in PDEX or EMBC? 15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 47.5% of Pro-Dex shares are held by insiders. Comparatively, 0.4% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor PDEX or EMBC? In the previous week, Embecta had 4 more articles in the media than Pro-Dex. MarketBeat recorded 5 mentions for Embecta and 1 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.94 beat Embecta's score of 0.54 indicating that Pro-Dex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPro-Dex beats Embecta on 9 of the 15 factors compared between the two stocks. Get Pro-Dex News Delivered to You Automatically Sign up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDEX vs. The Competition Export to ExcelMetricPro-DexMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$155M$15.49B$5.56B$9.34BDividend YieldN/A1.46%3.80%4.06%P/E Ratio16.8818.3328.0819.86Price / Sales2.862.29433.4499.92Price / Cash49.6416.9435.8457.94Price / Book5.233.788.255.67Net Income$2.13M$430.42M$3.24B$257.80M7 Day Performance5.02%-0.32%1.43%1.87%1 Month Performance15.74%1.35%8.02%10.92%1 Year Performance145.56%15.85%30.07%18.51% Pro-Dex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDEXPro-Dex2.1858 of 5 stars$47.27-0.5%$56.00+18.5%+137.5%$155M$53.84M16.88140EMBCEmbecta4.6885 of 5 stars$10.03-2.8%$19.33+92.8%-27.6%$603.13M$1.08B11.142,100Analyst ForecastBBNXBeta BionicsN/A$13.40-0.9%$23.44+75.0%N/A$586.18M$65.12M0.00294Positive NewsAVNSAVANOS MEDICAL2.8844 of 5 stars$11.87-3.9%N/A-48.6%$571.11M$687.80M-1.422,227BVSBioventus2.7668 of 5 stars$6.82-2.8%$13.75+101.6%-9.4%$560.22M$567.70M-11.181,200KIDSOrthoPediatrics4.2487 of 5 stars$21.24-5.5%$35.83+68.7%-36.0%$545.96M$204.73M-12.14200RXSTRxSight2.2897 of 5 stars$12.43-4.8%$37.90+204.9%-84.4%$530.31M$139.93M-18.55220Analyst DowngradeAXGNAxoGen2.1928 of 5 stars$11.36+3.9%$24.50+115.7%+22.7%$497.80M$187.34M-75.73450News CoverageAnalyst RevisionHigh Trading VolumeBFLYButterfly Network2.5573 of 5 stars$1.89-2.6%$3.50+85.2%+55.4%$479.74M$82.06M-6.52460SMLRSemler Scientific2.6307 of 5 stars$38.95-3.7%$71.00+82.3%+20.4%$451.08M$56.29M-14.92120DCTHDelcath Systems2.6119 of 5 stars$12.24-3.5%$24.00+96.1%+44.8%$441.94M$37.21M-24.4860News Coverage Related Companies and Tools Related Companies EMBC Competitors BBNX Competitors AVNS Competitors BVS Competitors KIDS Competitors RXST Competitors AXGN Competitors BFLY Competitors SMLR Competitors DCTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDEX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro-Dex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pro-Dex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.